Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection | EMBO Molecular Medicine
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19 | American Society of Nephrology
Should ACE-inhibitors and ARBs be stopped with COVID-19? — NephJC
Molecules | Free Full-Text | Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2 | HTML
ACE Inhibitor Pathway, Pharmacodynamics
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19 | Signal Transduction and Targeted Therapy
Should ACE-inhibitors and ARBs be stopped with COVID-19? — NephJC
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 | Critical Care | Full Text
ACE2 as a potential therapeutic target for pandemic COVID-19 - RSC Advances (RSC Publishing) DOI:10.1039/D0RA08228G
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy - eBioMedicine
Cells | Free Full-Text | The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients | HTML
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy - eBioMedicine
What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target | SpringerLink
Role of the ACE2/Angiotensin 1–7 Axis of the Renin–Angiotensin System in Heart Failure | Circulation Research
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 | NEJM
ACE2 as a potential therapeutic target for pandemic COVID-19 - RSC Advances (RSC Publishing)
COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury | Revista Colombiana de Cardiología
ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad | European Respiratory Society
Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 ...
Frontiers | Regulated Intramembrane Proteolysis of ACE2: A Potential Mechanism Contributing to COVID-19 Pathogenesis?
